What will be ACST patient population? They can't compete with AMRN on under 500 TG levels since they have no trial for that, so maybe just the smaller 500-1,500 hyperTrig population of the Trilogy trials? However they probably won't be best in class since they don't have outcomes trial whereas Vascepa proved to reduce cadio events. Right?
Market Data 
Markets 
AI
